June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Efficacy of Aflibercept in Treatment-naïve Neovascular Age-related Macular Degeneration: One-Year Real World Outcomes
Author Affiliations & Notes
  • Clara Vazquez-Alfageme
    NIHR Moorfields Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Praveen J Patel
    NIHR Moorfields Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Robin Hamilton
    NIHR Moorfields Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships Clara Vazquez-Alfageme, None; Praveen Patel, Bayer UK (C), Bayer UK (R), Novartis UK (C), Novartis UK (R); Robin Hamilton, Alcon (F), Allergan (F), Bayer (F), Bayer (R), Ellex (F), Ellex (R), Novartis (F), Novartis (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4613. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Clara Vazquez-Alfageme, Praveen J Patel, Robin Hamilton; Efficacy of Aflibercept in Treatment-naïve Neovascular Age-related Macular Degeneration: One-Year Real World Outcomes. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4613.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The VIEW 1 and 2 studies of aflibercept (Eylea®, Bayer Pharma, Germany) treatment for neovascular AMD (nAMD) showed positive results with an 8-weekly interval between injections in the maintenance phase of the first year of treatment. However, outcomes of clinical trials cannot always be replicated in clinical practice. In this study we aim to report real-world anatomical and functional outcomes of aflibercept treatment for nAMD after 1 year of treatment.

Methods: This was a retrospective, observational, study of 1 year treatment outcomes of treatment-naive patients with nAMD. Patients with eyes treated at Moorfields Eye Hospital (and satellite clinics) with a minimum of 4 aflibercept injections and 12 ± 1 months of follow up were included in this analysis. Aflibercept was injected every 2 months after 3 initial monthly doses in the first year and after the seventh injection, a treat and extend regimen was used. The primary outcome measure was the percentage of patients who maintained vision at the end of one-year follow up (loss of < 15 ETDRS letters). Secondary outcomes included mean change in best-corrected visual acuity (BCVA); percentage gaining ≥ 15 letters and mean change in central macular thickness (CMT).

Results: Outcomes of 52 eyes of 52 patients were included in the analysis. 96.2% maintained vision at the end of the follow up with a mean of 7.2 ± 1.6 injections. 26.9% gained at least 15 letters with a mean gain of 8.5 ± 13.4 letters and a reduction of 90.4 ± 86.5mm in CMT.

Conclusions: Aflibercept use for nAMD in routine clinical practice resulted in similar visual outcomes after 1 year to outcomes seen in the VIEW 1 and 2 clinical trials.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×